Larimar Therapeutics Past Earnings Performance

Past criteria checks 0/6

Larimar Therapeutics's earnings have been declining at an average annual rate of -7.6%, while the Biotechs industry saw earnings growing at 12.7% annually.

Key information

-7.6%

Earnings growth rate

39.3%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	n/a
Return on equity	-45.2%
Net Margin	n/a
Last Earnings Update	31 Dec 2023

Recent past performance updates

No updates

Recent updates

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Nov 13

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

May 19

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 02

Laramar Therapeutics issued patent for lead pipeline candidate

Oct 20

Larimar Therapeutics prices ~$70M stock offering

Sep 14

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Sep 02

Larimar Therapeutics GAAP EPS of -$0.47

Aug 11

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Mar 21

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Dec 18

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

May 26

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 08

Revenue & Expenses Breakdown
Beta

How Larimar Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:LRMR Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	-37	14	28
30 Sep 23	-33	14	24
30 Jun 23	-33	13	23
31 Mar 23	-33	12	23
31 Dec 22	-35	12	24
30 Sep 22	-35	12	23
30 Jun 22	-44	12	32
31 Mar 22	-47	12	35
31 Dec 21	-51	12	38
30 Sep 21	-56	13	43
30 Jun 21	-49	14	36
31 Mar 21	-48	13	35
31 Dec 20	-42	11	31
30 Sep 20	-34	9	26
30 Jun 20	-33	6	27
31 Mar 20	-25	4	22
31 Dec 19	-23	2	21

Quality Earnings: LRMR is currently unprofitable.

Growing Profit Margin: LRMR is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: LRMR is unprofitable, and losses have increased over the past 5 years at a rate of 7.6% per year.

Accelerating Growth: Unable to compare LRMR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LRMR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).

Return on Equity

High ROE: LRMR has a negative Return on Equity (-45.21%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Larimar Therapeutics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

New major risk - Revenue and earnings growth

Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’S Ataxia

New minor risk - Shareholder dilution

Larimar Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000005 million.

Larimar Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $50 million.

Price target increased by 41% to US$16.24

Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial

Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

Larimar Therapeutics Reports Preliminary Top-Line Data from Phase 2 Trial’S 25 Mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’S Ataxia

Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Price target decreased to US$10.59

High number of new and inexperienced directors

Laramar Therapeutics issued patent for lead pipeline candidate

CEO, President & Director recently bought US$100k worth of stock

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients

Larimar Therapeutics prices ~$70M stock offering

Price target increased to US$6.23

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Larimar Therapeutics, Inc. Provides Updates on CTI-1601 Clinical Program Following A Type C Meeting with the U.S. Food and Drug Administration

Larimar Therapeutics GAAP EPS of -$0.47

Price target increased to US$5.88

High number of new and inexperienced directors

Larimar Therapeutics, Inc., Annual General Meeting, May 10, 2022

Larimar Therapeutics, Inc. Announces Not Stand for Re-Election of Thomas O. Daniel as Board of Director

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Price target decreased to US$13.50

Larimar Therapeutics, Inc. Provides Update on CTI-1601 Clinical Program

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Independent Director recently bought US$496k worth of stock

Larimar Therapeutics, Inc. Reports FDA Clinical Hold on CTI-1601

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

Larimar Therapeutics, Inc. announced that it expects to receive $95.273757 million in funding from Deerfield Management Company, L.P. and other investors

Larimar Therapeutics, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

New 90-day low: US$17.75

Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index

Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update

Larimar completes dosing in Friedreich’s Ataxia, provides program update

Larimar Therapeutics (LRMR) Investor Presentation - Slideshow

New 90-day high: US$22.50

Larimar Therapeutics reports Q3 results

Larimar Therapeutics Announces Formation of Scientific Advisory Board

New 90-day high: US$18.91

New 90-day high - US$16.00

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Microcap Value Index

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta